Page last updated: 2024-08-21

isoxazoles and Lymphoma, Large-Cell, Anaplastic

isoxazoles has been researched along with Lymphoma, Large-Cell, Anaplastic in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aichler, M; Baumgart, A; Buck, A; Dechow, T; Feuchtinger, A; Graf, N; Herrmann, K; Jünger, A; Keller, U; Li, Z; Peschel, C; Schwaiger, M; Walch, A1

Other Studies

1 other study(ies) available for isoxazoles and Lymphoma, Large-Cell, Anaplastic

ArticleYear
FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
    Cancer research, 2012, Oct-01, Volume: 72, Issue:19

    Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Survival; Dideoxynucleosides; Enzyme Inhibitors; Everolimus; Female; Flow Cytometry; Fluorine Radioisotopes; Fluorodeoxyglucose F18; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lymphoma, Large-Cell, Anaplastic; Mice; Mice, SCID; Positron-Emission Tomography; Protein-Tyrosine Kinases; Resorcinols; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays

2012